A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial

• DOI: 10.1007/s40120-023-00473-w
• Publication Date: 2023-04-03T10:11:46Z
• Authors: Amir Abbas Tahami...; Weicheng Ye; Aditya Sardesai; Henri Folse; Ameya Chavan; Elena Aruffo; Quanwu Zhang
• Keywords: Cognitive Decline

Alzheimer's disease (AD), a progressive neurodegenerative disease, is the main cause of dementia and one leading causes death for elderly people in USA. Lecanemab humanized IgG1 monoclonal antibody targeting amyloid protofibrils treatment early AD [i.e., mild cognitive impairment (MCI) or dementia]. In recent 18-month phase III trial, using double-blind, placebo-controlled design, lecanemab led to reduced brain burden significant improvements functional abilities individuals with AD. An evidence-based patient-level simulation model was updated estimate long-term health outcomes plus standard care (SoC) compared SoC alone patients evidence burden, trial data published literature. The progression described by changes underlying biomarkers AD, including measures tau, their connection clinical presentation assessed through various scales cognition function. estimated slow moderate severe stages reduce time spent these more advanced states. associated gain 0.71 quality-adjusted life-years (QALYs), 2.95-year delay mean dementia, reduction 0.11 years institutional care, an additional 1.07 community as shown base-case study. Improved were demonstrated when initiated earlier based on age, severity, tau pathology, resulting gains QALYs ranging from 0.77 1.09 years, 0.4 subset, model. study findings demonstrate potential value slowing down prolonging which significantly benefits not only caregivers but also society overall. ClinicalTrials.gov identifier, NCT03887455.